Observational studyJournal of the American Heart Association2025
Association of Genetic Variants With Rivaroxaban Pharmacokinetics and Pharmacodynamics and Hemorrhage Risk Factors in Patients With Venous Thromboembolism.
Observational study in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Pharmacogenomics of Rivaroxaban: Association ofPharmaceutics · 2026Article
- Pharmacogenomics of direct oral anticoagulants: a systematic review and meta-analysis.Frontiers in cardiovascular medicine · 2026Review
- Pharmacogenetic variants in pharmacokinetic and pharmacodynamic pathways and clinical factors associated with bleeding risk in Thai patients receiving rivaroxaban: a case-control study.Therapeutic advances in drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRivaroxaban is a first-line agent for venous thromboembolism prophylaxis and treatment. However, its pharmacokinetics, pharmacodynamics, and bleeding risk exhibit significant interindividual variability. Known nongenetic factors alone cannot fully explain this variability, and the impact of genetic polymorphisms remains debated.
methodsFrom December 29, 2021, to May 11, 2023, 310 patients with venous thromboembolism treated with rivaroxaban were enrolled in this observational study from a tertiary hospital in Shanghai, China, based on predefined criteria. We assessed relationships between rivaroxaban concentrations, anti-Factor Xa levels, and coagulation parameters; examined the impact of 12 genes on concentrations and anti-Factor Xa levels; and followed up for at least 3 months to identify bleeding risk factors.
resultsRivaroxaban plasma concentration was significantly related to anti-Factor Xa levels (R
conclusionsPharmacogenetic monitoring and hemorrhage risk assessment may contribute to optimize its efficacy and safety. Larger-scale, global multicenter clinical trials are required to validate the potential gene loci for testing, including
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.